By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sera Prognostics today announced the closing of a $19.3 million Series A financing, which it plans to use to complete a clinical trial and launch its test for predicting preterm birth.

The Salt Lake City firm also announced the appointment of Gregory Critchfield as its new CEO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.